Polypeptide is a relatively common natural polymer, generally composed of multiple amino acids, and can form secondary structures (α-helix, β-sheet) through hydrogen bonds. Polypeptides can be prepared by solid-phase synthesis, which is simple. Peptides are biologically active and have the advantages of easy metabolism, low immunogenicity, and low toxicity and side effects. In recent years, due to the advantages of strong pharmacological activity, high specificity, and low toxicity, polypeptide drugs have become biological macromolecules with broad application prospects in drug development, and their status in the prevention and treatment of diseases is becoming increasingly important. On the one hand, with the wide application of biotechnology, more and more ​protein and peptide drugs have become hot spots in drug development, such as cytokine drugs such as interferon and growth factors, and recombinant hormone drugs. However, such drugs have many defects such as poor stability, short biological half-life, sensitivity to enzyme and pH changes, large molecular weight, and difficulty passing through the gastrointestinal biomucosal membrane, which increases the difficulty of research and development. In order to overcome the above shortcomings, CD BioSciences has developed an in vivo polypeptide delivery system using nanoparticles as carriers. The polypeptide encapsulated by our carrier has good stability, long half-life in vivo, obvious therapeutic effect, and low toxic and side effects of the drug.

Figure 1. Peptide-based drug delivery systems.(Berillo D, et al.; 2021)

CD BioSciences provides customized delivery strategies, through the precise design and modification of delivery vehicles, as well as advanced technology platforms, can help you solve:

• There is no suitable method for peptide delivery to specific tissues and organs in the body;
• Peptides cannot easily cross cell membranes due to their size and surface chemistry
• Low payload of in vivo delivery systems
• Peptides are diluted and degraded during in vivo delivery without protection
• Poor stability of peptide in vivo
• The release of peptides in the body is uncontrolled
• Etc…

Key Features

Nanoparticles

• PLGA
• CS
• solid lipid nanoparticles (SLN)
• Inorganic nanoparticles

Liposomes

• Long-circulating liposomes
• Targeting liposomes
• Long circulation targeted liposomes
• Multivesicular liposomes

Flexible nanoliposomes

Microspheres

Hydrogels

• Temperature sensitive hydrogel
• Ph sensitive hydrogel

Our Advantage:

• CD BioSciences can provide professional peptide in vivo delivery system to achieve efficient in vivo delivery;
• Our delivery system can add modified ligands to achieve targeting;
• The in vivo peptide delivery system has low toxicity to the body and is safe to use
• In vivo peptide delivery system Carriers protect peptides from dilution and degradation during in vivo delivery
• The delivery system can achieve timing, location, fixed rate and targeted release in vivo, so that experimental animals have a long-lasting effect after a single injection
• The system load is high, and the delivery requirements of different doses can be fulfilled
• Professional design and service team to provide you with reliable service and technical support feedback technical report in time

CD BioSciences is focused on developing in vivo delivery systems using our core technologies. With our high-quality products and services, your delivery effect will be greatly improved. If you can't find the perfect in vivo delivery system, you can contact us. We can provide one-to-one personal customization services.

References

1. LIN S N, et al.; Research progress in nanoparticles as anticancer drug carrier. Chin German J Glin Oncol. 2013, 40( 6): 363-366．
2. DU L, et al.; In-vitro /in-vivo studies of the biodegradable poly-(D，L-lactide-co-glycolide) microspheres of a novel luteinizing hormone-releasing hormone antagonist for prostate cancer treatment. Anticancer Drugs. 2011, 22 (3): 262-272．
3. SUN R S, et al.; Application of chitosan nanoparticle served as drug delivery system for cancer therapy. Chin J Clin Pharmacol Ther. 2021, 26(1) : 65-75．
4. BLASI P, et al.; Lipid nanoparticles for brain targeting II. Technological characterization. Coll Surf B Biointerfaces. 2013, 110(11) : 130-137．
5. CHEN Y, et al.; Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells. Mol Pharm. 2014, 11(8): 2495-2510．
6. Berillo D, et al.; Peptide-Based Drug Delivery Systems. Medicina (Kaunas). 2021, 57(11):1209.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.